AGILENT Q4 EARNINGS BEAT ESTIMATES WITH STRONG DIAGNOSTICS PERFORMANCE | $A (+0,38 %)
QUARTERLY PERFORMANCE
- $A Reports Q4 adjusted EPS of $1.46, surpassing $1.41 consensus estimate
- Total revenue reached $1.70 billion, exceeding $1.67 billion forecast
- Adjusted net income of $418 million topped expectations of $405.1 million
SEGMENT BREAKDOWN
- Life Sciences & Applied Markets
* Revenue: $833 million (vs. estimate $845.4 million)
* Segment showed slight underperformance against projections
- Diagnostics & Genomics
* Revenue: $442 million (vs. estimate $417.3 million)
* Demonstrated strong outperformance, exceeding expectations
- Agilent Crosslab
* Revenue: $426 million (vs. estimate $423.6 million)
* Maintained steady performance above estimates
FORWARD GUIDANCE
Fiscal Year 2024 Outlook:
- Revenue projected between $6.790-$6.870 billion
- Represents growth of:
* 4.3% to 5.5% (reported basis)
* 2.5% to 3.5% (core basis)
Q1 FY2024 Guidance:
- Revenue expected between $1.650-$1.680 billion
- Projects range from -0.5% to +1.3% (reported)
- Core growth range: -2.0% to -0.2%
MANAGEMENT PERSPECTIVE
CEO Padraig McDonnell noted continued market recovery and solid execution by the Agilent team in Q4, supporting the company's positive performance against estimates.